Pemvidutide vs Survodutide
The two GLP-1/glucagon dual agonists, both investigational, chasing different prizes: one is optimizing body composition, the other has already read out Phase 3.
Pemvidutide
A GLP-1/glucagon dual agonist aimed specifically at preserving lean mass while cutting liver fat; real Phase 2 MASLD data, but Phase 3 has not started and it remains fully investigational.
Full Pemvidutide evidence reviewSurvodutide
A GLP-1/glucagon dual agonist in Phase 3 for both obesity and MASH; genuine placebo-controlled efficacy data in both indications, but no approval anywhere yet.
Full Survodutide evidence reviewSide by side
| Pemvidutide | Survodutide | |
|---|---|---|
| Marketed for | Weight loss, MASLD/MASH | Weight loss, MASH |
| Evidence grade | Clinical data | Clinical data |
| Family | GLP-1 / incretin | GLP-1 / incretin |
| Regulatory status | Investigational | Investigational |
| How it's obtained | Research-only | Research-only |
| Key human source | Phase 2 MASLD RCT, 2025 | Phase 2 obesity RCT, 2024 |
marks a row where the two differ. Evidence grades come from our evidence matrix, which grades each molecule on the human data for the use it is marketed for.
Our verdict
Survodutide is further along by a wide margin. Its Phase 3 SYNCHRONIZE-1 (n=725, 76 weeks) reported about −16.6% mean weight loss against −3.2% on placebo, and SYNCHRONIZE-MASLD (n=216) reported 84.2% of participants achieving at least a 30% reduction in liver fat with 61.0% normalizing it. Pemvidutide is still Phase 2: MOMENTUM (391 adults, 48 weeks) produced about −15.6% at 2.4 mg versus −2.2% on placebo, and its IMPACT Phase 2b trial met MASH resolution without worsening fibrosis at 24 weeks. Pemvidutide’s distinguishing claim is body composition — Altimmune reported roughly 74.5% of the weight lost was fat and 25.5% lean — but that is a company-reported ratio framed around the hypothesis the program was designed to test, not a finding another trial has confirmed, and it should not be read as an established advantage. Neither drug is approved anywhere.
Pemvidutide fits if
You care specifically about the lean-mass-preservation hypothesis and want to watch whether it survives a Phase 3 that has not started yet.
Survodutide fits if
You want the dual agonist with real Phase 3 data in both obesity and liver disease — the one likelier to reach a regulator first.